Key Points
- SVP Michael Pisetsky sold 1,335 shares on April 2 at an average price of $12.86 for $17,168.10, trimming his stake by 0.47% to 282,840 shares valued at about $3.64 million.
- Wall Street leans positive with six Buy ratings, one Sell, a consensus grade of "Moderate Buy" and an average price target of $24.67.
- Si‑Bone beat quarterly EPS expectations (reported -$0.04 vs. -$0.13) and revenue was roughly in line, but the company remains unprofitable with negative margins and analysts forecasting about -$0.78 EPS for the fiscal year.
SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael Pisetsky sold 1,335 shares of SiBone stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $12.86, for a total value of $17,168.10. Following the sale, the senior vice president directly owned 282,840 shares in the company, valued at $3,637,322.40. The trade was a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
SiBone Stock Performance
SIBN stock opened at $13.12 on Friday. SiBone has a 1-year low of $12.15 and a 1-year high of $21.89. The company has a current ratio of 8.55, a quick ratio of 7.21 and a debt-to-equity ratio of 0.20. The business's 50 day moving average is $14.62 and its 200-day moving average is $16.37. The firm has a market cap of $579.51 million, a P/E ratio of -29.82 and a beta of 0.77.
SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.09. The business had revenue of $56.35 million during the quarter, compared to the consensus estimate of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. Equities analysts anticipate that SiBone will post -0.78 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have recently commented on SIBN. TD Cowen boosted their target price on shares of SiBone from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, February 24th. Canaccord Genuity Group increased their target price on shares of SiBone from $26.00 to $27.00 and gave the stock a "buy" rating in a research report on Wednesday, December 17th. Wall Street Zen raised shares of SiBone from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. Weiss Ratings restated a "sell (d-)" rating on shares of SiBone in a research report on Monday, December 29th. Finally, Needham & Company LLC upped their price objective on shares of SiBone from $24.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, December 16th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.67.
Get Our Latest Stock Analysis on SiBone
Institutional Investors Weigh In On SiBone
Hedge funds and other institutional investors have recently made changes to their positions in the company. First Light Asset Management LLC raised its position in shares of SiBone by 162.4% during the fourth quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company's stock worth $99,249,000 after acquiring an additional 3,115,001 shares during the last quarter. American Century Companies Inc. boosted its holdings in SiBone by 22.5% in the third quarter. American Century Companies Inc. now owns 2,838,107 shares of the company's stock valued at $41,777,000 after acquiring an additional 521,683 shares during the last quarter. Vanguard Group Inc. increased its position in SiBone by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company's stock worth $49,331,000 after purchasing an additional 11,566 shares during the period. Nuveen LLC increased its position in SiBone by 5.1% in the fourth quarter. Nuveen LLC now owns 1,421,946 shares of the company's stock worth $28,041,000 after purchasing an additional 69,229 shares during the period. Finally, Impax Asset Management Group plc raised its holdings in SiBone by 17.1% during the 4th quarter. Impax Asset Management Group plc now owns 1,200,010 shares of the company's stock worth $23,664,000 after purchasing an additional 175,000 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.
SiBone Company Profile
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
